Une nouvelle recherche de la Cleveland Clinic montre pour la première fois que l'ibrutinib (ibrutinib) approuvé par la FDA pour le lymphome et la leucémie peut également aider à traiter les tumeurs cérébrales les plus courantes et les plus mortelles, et pourrait un jour être utilisé chez les patients atteints de glioblastome et améliorer les taux de survie.
Selon le rapport de l'American Brain Tumor Association, le taux de survie du glioblastome est très faible et la survie médiane des patients recevant un traitement standard est inférieure à 15 mois. Le glioblastome est la tumeur cérébrale primaire la plus meurtrière et il est très résistant aux traitements actuels. Il est urgent de fournir à ces patients de nouveaux traitements dès que possible.
In an earlier study, Bao and colleagues found that gliome stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain tumeurs in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
